ICER, CADTH, and NICE collaborate to increase transparency in health technology evaluations
The Institute for Clinical and Economic Review (ICER), the Canadian Agency for Drugs and Technologies in Health (CADTH), and the UK’s National Institute for Health and Care Excellence (NICE) have announced changes to the way confidential information about health technologies is handled. The aim is to streamline processes and increase transparency while balancing the need to protect confidential information. The three organizations have been working together to create a more consistent approach to handling clinical data. ICER has updated its academic-in-confidence data policy, reducing the period during which data is redacted from external and public documents from 18 months to 12 months. These changes will come into effect in May 2023.
Recent Posts
Sanofi’s Rilzabrutinib Receives Orphan Designation for IgG4-Related Disease
Sanofi's rilzabrutinib has received orphan drug designation from the European Medicines Agency for treating IgG4-related disease (IgG4-RD). This reversible covalent Bruton's tyrosine kinase (BTK) inhibitor earned the designation based on promising Phase 2 study results. The findings, presented at...
PADCEV KEYTRUDA Urothelial Cancer: Advancements in Survival Outcomes and Economic Impact
A newly published Pfizer press release presents clinical trial results indicating that the combination therapy PADCEV™ (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) significantly improves overall survival in patients with previously untreated locally advanced or metastatic urothelial c...
France’s HAS Denies Ribociclib Breast Cancer Therapy for Early HR+/HER2- Patients
Ribociclib breast cancer therapy has been closely scrutinized as an adjuvant treatment for patients with early-stage HR-positive, HER2-negative breast cancer at high risk of recurrence. If you’re wondering, “Why did France’s HAS reject reimbursement for ribociclib in this setting, and how might i...